Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.

IF 3.6 2区心理学 Q1 PSYCHOLOGY, MULTIDISCIPLINARY

Annals of Behavioral Medicine Pub Date : 2024-11-16 DOI:10.1093/abm/kaae063

Stacy M Post, Rebecca K Hoffman, Junhan Chen, Michelle L Stock, Susan Persky

{"title":"Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.","authors":"Stacy M Post, Rebecca K Hoffman, Junhan Chen, Michelle L Stock, Susan Persky","doi":"10.1093/abm/kaae063","DOIUrl":null,"url":null,"abstract":"Background: Glucagon-like-peptide-1 receptor agonists (GLP-1s) are a newer class of obesity medications that have garnered significant attention by the public and media. Media reports suggest that medical interventions such as GLP-1s are often perceived as weight loss \"shortcuts.\"Purpose: The present experimental research tested the effect of exposure to medical weight loss interventions on GLP-1 policy support, dependent on body mass index.Methods: A sample of 440 participants (Mage= 37, SD = 12.6) were randomly assigned to read about a woman who lost 15% of her body weight either with a GLP-1, bariatric surgery, or diet/exercise. Participants reported on beliefs that the woman took a weight loss \"shortcut\" and support for three policies expanding GLP-1 coverage.Results: Exposure to a woman who lost weight with GLP-1 or bariatric surgery (vs. diet/exercise) led to higher GLP-1 policy support. However, such exposure was also indirectly associated with lower policy support, partially mediated by weight loss \"shortcut\" beliefs.Conclusions: This study provides evidence that exposure to medical weight loss interventions leads to higher GLP-1 policy support. Exposure may also, indirectly, lead to lower policy support due to beliefs that such interventions are shortcuts. Findings have implications for policymakers who are interested in how perceptions of medical weight loss interventions influence support for obesity treatments and related health policies.","PeriodicalId":7939,"journal":{"name":"Annals of Behavioral Medicine","volume":" ","pages":"857-862"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568355/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Behavioral Medicine","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1093/abm/kaae063","RegionNum":2,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glucagon-like-peptide-1 receptor agonists (GLP-1s) are a newer class of obesity medications that have garnered significant attention by the public and media. Media reports suggest that medical interventions such as GLP-1s are often perceived as weight loss "shortcuts."

Purpose: The present experimental research tested the effect of exposure to medical weight loss interventions on GLP-1 policy support, dependent on body mass index.

Methods: A sample of 440 participants (Mage= 37, SD = 12.6) were randomly assigned to read about a woman who lost 15% of her body weight either with a GLP-1, bariatric surgery, or diet/exercise. Participants reported on beliefs that the woman took a weight loss "shortcut" and support for three policies expanding GLP-1 coverage.

Results: Exposure to a woman who lost weight with GLP-1 or bariatric surgery (vs. diet/exercise) led to higher GLP-1 policy support. However, such exposure was also indirectly associated with lower policy support, partially mediated by weight loss "shortcut" beliefs.

Conclusions: This study provides evidence that exposure to medical weight loss interventions leads to higher GLP-1 policy support. Exposure may also, indirectly, lead to lower policy support due to beliefs that such interventions are shortcuts. Findings have implications for policymakers who are interested in how perceptions of medical weight loss interventions influence support for obesity treatments and related health policies.

查看原文本刊更多论文

暴露于 GLP-1 受体激动剂和使用减肥手术对肥胖症的政策支持。

背景：胰高血糖素样肽-1受体激动剂（GLP-1s）是一类较新的肥胖症药物，已引起公众和媒体的极大关注。媒体报道显示，GLP-1s 等医疗干预措施往往被视为减肥 "捷径"。目的：本实验研究测试了接触医疗减肥干预措施对 GLP-1 政策支持的影响，这取决于体重指数：方法：440 名参与者（平均年龄 = 37 岁，平均标准偏差 = 12.6）被随机分配阅读关于一名妇女通过 GLP-1、减肥手术或节食/运动减肥 15%的报道。参与者报告了他们是否认为该妇女走了一条减肥 "捷径"，以及是否支持扩大 GLP-1 治疗范围的三项政策：结果：接触过通过 GLP-1 或减肥手术（相对于节食/运动）减肥的女性，对 GLP-1 政策的支持率较高。然而，这种接触也与较低的政策支持率间接相关，部分原因是减肥 "捷径 "信念：本研究提供的证据表明，接触医疗减肥干预会导致更高的 GLP-1 政策支持率。由于认为此类干预措施是捷径，接触此类干预措施也可能间接导致较低的政策支持率。研究结果对政策制定者很有意义，他们对医疗减肥干预措施的看法如何影响对肥胖症治疗和相关健康政策的支持很感兴趣。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Behavioral Medicine PSYCHOLOGY, MULTIDISCIPLINARY-

CiteScore

7.00

自引率

5.30%

发文量

期刊介绍： Annals of Behavioral Medicine aims to foster the exchange of knowledge derived from the disciplines involved in the field of behavioral medicine, and the integration of biological, psychosocial, and behavioral factors and principles as they relate to such areas as health promotion, disease prevention, risk factor modification, disease progression, adjustment and adaptation to physical disorders, and rehabilitation. To achieve these goals, much of the journal is devoted to the publication of original empirical articles including reports of randomized controlled trials, observational studies, or other basic and clinical investigations. Integrative reviews of the evidence for the application of behavioral interventions in health care will also be provided. .